CoChat

Diabetes: Risk factor and translational therapeutic implications for Alzheimer's disease

Open access
Cummings, Jeffrey, Ortiz, Andrew, Castellino, Janelle, Kinney, Jefferson · 2022 · European Journal of Neuroscience
Cited by 48

The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.

Abstract

Type 2 diabetes mellitus (T2DM) and Alzheimer's disease (AD) commonly co‐occur. T2DM increases the risk for AD by approximately twofold. Animal models provide one means of interrogating the relationship of T2DM to AD and investigating brain insulin resistance in the pathophysiology of AD. Animal models show that persistent hyperglycaemia results in chronic low‐grade inflammation that may contribute to the development of neuroinflammation and accelerate the pathobiology of AD. Epidemiological studies suggest that patients with T2DM who received treatment with specific anti‐diabetic agents have a decreased risk for the occurrence of AD and all‐cause dementia. Agents such as metformin ameliorate T2DM and may have other important systemic effects that lower the risk of AD. Glucagon‐like peptide 1 (GLP‐1) agonists have been associated with a decreased risk for AD in patients with T2DM. Both insulin and non‐insulin anti‐diabetic treatments have been evaluated for the treatment of AD in clinical trials. In most cases, patients included in the trials have clinical features of AD but do not have T2DM. Many of the trials were conducted prior to the use of diagnostic biomarkers for AD. Trials have had a wide range of durations and population sizes. Many of the agents used to treat T2DM do not cross the blood brain barrier, and the effects are posited to occur via lowering of peripheral hyperglycaemia and reduction of peripheral and central inflammation. Clinical trials of anti‐diabetic agents to treat AD are ongoing and will provide insight into the therapeutic utility of these agents.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/ejn.15619

Cites

74 of 74 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 74 references

Cited by

Metadata

Authors
Cummings, J., Ortiz, A., Castellino, J., & Kinney, J.
Venue
European Journal of Neuroscience
Publisher
Wiley
Published
2022-02-23
Volume
56
Issue
9
Pages
5727-5757
ISSN
  • 0953-816X (ISSN-L)
  • 1460-9568
OpenAlex
W4210423403
Cited by
48
References
74
FWCI
5.52
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.